A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma

Published:2011-08-24 Issue:10 Volume:13 Page:1143-1150
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:Neuro-Oncology

Author:

Kreisl T. N.,Zhang W.,Odia Y.,Shih J. H.,Butman J. A.,Hammoud D.,Iwamoto F. M.,Sul J.,Fine H. A.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Clinical Neurology,Oncology

Link

http://academic.oup.com/neuro-oncology/article-pdf/13/10/1143/3588888/nor091.pdf

Reference20 articles.

1. Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

2. Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

3. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of low-dose bevacizumab on health-related quality of life in patients with recurrent high-grade glioma: A retrospective clinical study;Journal of Clinical Neuroscience;2024-02

2. Pathways to hypermutation in high-grade gliomas: Mechanisms, syndromes, and opportunities for immunotherapy;Neuro-Oncology Advances;2024-01-01

3. Clinical Trials in the Brain Tumour Population: Challenges and Strategies for the Future;Current Oncology Reports;2023-03-28

4. Origin, activation, and targeted therapy of glioma-associated macrophages;Frontiers in Immunology;2022-10-06

5. Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors;ESMO Open;2022-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3